HK1249508A1 - 氯喹和克立咪唑化合物用於治疗炎症和癌性病症的用途 - Google Patents

氯喹和克立咪唑化合物用於治疗炎症和癌性病症的用途 Download PDF

Info

Publication number
HK1249508A1
HK1249508A1 HK18109030.3A HK18109030A HK1249508A1 HK 1249508 A1 HK1249508 A1 HK 1249508A1 HK 18109030 A HK18109030 A HK 18109030A HK 1249508 A1 HK1249508 A1 HK 1249508A1
Authority
HK
Hong Kong
Prior art keywords
treatment
chloroquine
inflammatory
cancerous conditions
clemizole
Prior art date
Application number
HK18109030.3A
Other languages
English (en)
Chinese (zh)
Inventor
Jeffrey S. Glenn
Edward A. Pham
Original Assignee
Eiger Group International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Group International, Inc. filed Critical Eiger Group International, Inc.
Publication of HK1249508A1 publication Critical patent/HK1249508A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18109030.3A 2015-06-30 2016-06-30 氯喹和克立咪唑化合物用於治疗炎症和癌性病症的用途 HK1249508A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30
US62/187,061 2015-06-30
PCT/US2016/040566 WO2017004454A1 (en) 2015-06-30 2016-06-30 Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions

Publications (1)

Publication Number Publication Date
HK1249508A1 true HK1249508A1 (zh) 2018-11-02

Family

ID=57609247

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109030.3A HK1249508A1 (zh) 2015-06-30 2016-06-30 氯喹和克立咪唑化合物用於治疗炎症和癌性病症的用途

Country Status (14)

Country Link
US (3) US10688083B2 (enExample)
EP (1) EP3317274A4 (enExample)
JP (3) JP7068827B2 (enExample)
KR (2) KR20180032578A (enExample)
CN (2) CN107922404B (enExample)
AU (4) AU2016288699B2 (enExample)
CA (2) CA2989634C (enExample)
HK (1) HK1249508A1 (enExample)
IL (4) IL300476B2 (enExample)
MX (3) MX394605B (enExample)
NZ (1) NZ776616A (enExample)
TW (3) TWI771272B (enExample)
WO (1) WO2017004454A1 (enExample)
ZA (2) ZA201708471B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300476B2 (en) * 2015-06-30 2024-07-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
GB201702160D0 (en) * 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
US12372530B2 (en) * 2017-11-15 2025-07-29 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) * 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
AU2003243409A1 (en) 2002-06-05 2003-12-22 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
ZA200505996B (en) * 2003-02-14 2006-12-27 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
TW200902047A (en) 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003219160A1 (en) * 2003-03-12 2004-09-30 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
BRPI0415935A (pt) * 2003-10-27 2007-01-02 Vertex Pharma combinações para tratamento de hcv
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101193622A (zh) 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
US20090220583A1 (en) * 2005-06-09 2009-09-03 Lena Pereswetoff-Morath Method and composition for treating inflammatory disorders
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
JP5715820B2 (ja) * 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
WO2009045443A2 (en) * 2007-10-02 2009-04-09 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
EP2408449A4 (en) * 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
US9351964B2 (en) * 2009-05-27 2016-05-31 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
PL2460403T3 (pl) * 2009-07-31 2019-11-29 Smc Global Asset Inc Mysi model stłuszczeniowego zapalenia wątroby-raka wątroby
AU2010282239A1 (en) * 2009-08-14 2012-03-08 Revivicor, Inc. Multi-transgenic pigs for diabetes treatment
US9415046B2 (en) 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
EP2488180A4 (en) * 2009-10-12 2013-03-27 Ipca Lab Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
JP6185473B2 (ja) * 2011-09-16 2017-08-23 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物
JPWO2013125543A1 (ja) * 2012-02-20 2015-07-30 武田薬品工業株式会社 複素環化合物
US20130273003A1 (en) * 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
BR112014029115A8 (pt) * 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
TW201402556A (zh) * 2012-05-30 2014-01-16 Toyama Chemical Co Ltd 氘化含氮雜環羧醯胺衍生物或其鹽
WO2014031769A2 (en) * 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
IL300476B2 (en) * 2015-06-30 2024-07-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions

Also Published As

Publication number Publication date
JP2018519340A (ja) 2018-07-19
TW201717941A (zh) 2017-06-01
IL279020A (enExample) 2020-12-31
MX2023003792A (es) 2023-04-26
IL310969A (en) 2024-04-01
IL279020B2 (en) 2023-07-01
ZA201708471B (en) 2022-05-25
WO2017004454A8 (en) 2018-01-25
AU2023201397B2 (en) 2024-10-03
JP2024083475A (ja) 2024-06-21
IL300476B1 (en) 2024-03-01
MX394605B (es) 2025-03-24
AU2021201234A1 (en) 2021-03-11
TW202317103A (zh) 2023-05-01
TWI771272B (zh) 2022-07-21
NZ776616A (en) 2024-11-29
CN107922404B (zh) 2021-06-29
US20210052553A1 (en) 2021-02-25
MX2017016681A (es) 2018-07-06
AU2023201397A1 (en) 2023-04-06
JP7068827B2 (ja) 2022-05-17
KR20180032578A (ko) 2018-03-30
US12090141B2 (en) 2024-09-17
AU2016288699A1 (en) 2018-01-18
MX2022008100A (es) 2022-07-11
TWI881480B (zh) 2025-04-21
IL279020B1 (en) 2023-03-01
NZ738291A (en) 2021-06-25
EP3317274A4 (en) 2019-05-08
IL300476B2 (en) 2024-07-01
IL300476A (en) 2023-04-01
BR112017028601A2 (pt) 2018-08-28
ZA202004136B (en) 2025-08-27
TW202402283A (zh) 2024-01-16
JP7470151B2 (ja) 2024-04-17
US20240398761A1 (en) 2024-12-05
WO2017004454A1 (en) 2017-01-05
TWI830262B (zh) 2024-01-21
US10688083B2 (en) 2020-06-23
CA2989634A1 (en) 2017-01-05
CN107922404A (zh) 2018-04-17
CA3178499A1 (en) 2017-01-05
AU2016288699B2 (en) 2020-11-26
AU2024266943A1 (en) 2024-12-19
US20180200228A1 (en) 2018-07-19
CN113274386A (zh) 2021-08-20
KR20230129590A (ko) 2023-09-08
EP3317274A1 (en) 2018-05-09
CA2989634C (en) 2022-12-06
IL256233A (en) 2018-02-28
JP2022105149A (ja) 2022-07-12

Similar Documents

Publication Publication Date Title
HK1249508A1 (zh) 氯喹和克立咪唑化合物用於治疗炎症和癌性病症的用途
IL264049A (en) Compounds, preparations and methods for treating the disease
EP3227317A4 (en) Methods and compositons for treating cancer
IL268469B (en) 2-Heteroaryl-3-oxo-3,2-dihydropyridazine-4-carboxamides for cancer treatment
IL264156A (en) Compounds, preparations and methods for treating the disease
EP3099274A4 (en) Vascular and bodily duct treatment devices and methods
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
IL264176B1 (en) Methods and preparations for the treatment of cancer
HK1252037A1 (zh) 治疗炎性疾病的方法
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
EP3285874A4 (en) Compositions and methods for treating mycobacteria infections and lung disease
EP3310385A4 (en) Methods and compositions for treating fibrotic diseases
WO2017044807A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3188800A4 (en) Compositions and methods for treating fibrosing disorders and cancer
EP3548007A4 (en) CANCER TREATMENT METHODS
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
ZA201808232B (en) Compositions and methods for the treatment of cancer
EP3240778A4 (en) Methods and agents for treating disease
EP3208262A4 (en) Compounds derived from 3-alkylamino-1h-indole acrylate, and the use thereof in the treatment of neurodegenerative diseases
EP3310338A4 (en) Compositions and methods for treating inflammatory disease or conditions
EP3270898A4 (en) Methods for the treatment of bladder cancer
HK40017104A (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
HK40005175A (en) Methods of treating biliary tract cancer